Sterling Capital Management LLC Has $1.85 Million Stake in IDEXX Laboratories, Inc. $IDXX

Sterling Capital Management LLC decreased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 35.1% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 3,293 shares of the company’s stock after selling 1,779 shares during the quarter. Sterling Capital Management LLC’s holdings in IDEXX Laboratories were worth $1,850,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. SHP Wealth Management bought a new position in IDEXX Laboratories during the fourth quarter valued at approximately $26,000. Virtus Advisers LLC bought a new stake in IDEXX Laboratories in the third quarter worth approximately $26,000. Park Place Capital Corp acquired a new position in shares of IDEXX Laboratories during the 4th quarter worth $29,000. Mowery & Schoenfeld Wealth Management LLC increased its stake in shares of IDEXX Laboratories by 58.8% during the 4th quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock worth $37,000 after purchasing an additional 20 shares during the last quarter. Finally, Wormser Freres Gestion increased its stake in shares of IDEXX Laboratories by 671.4% during the 4th quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock worth $37,000 after purchasing an additional 47 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

Shares of IDEXX Laboratories stock opened at $535.93 on Tuesday. The firm has a fifty day simple moving average of $558.11 and a 200-day simple moving average of $612.98. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a 1-year low of $506.91 and a 1-year high of $769.98. The stock has a market capitalization of $42.27 billion, a price-to-earnings ratio of 39.46, a PEG ratio of 3.02 and a beta of 1.56.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The business had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same period in the prior year, the firm earned $2.91 EPS. IDEXX Laboratories’s quarterly revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, sell-side analysts expect that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

Analyst Ratings Changes

IDXX has been the subject of several analyst reports. Citigroup started coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective for the company. Weiss Ratings raised shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday. UBS Group cut their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a report on Tuesday, April 28th. Stifel Nicolaus reduced their price target on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. Finally, Wall Street Zen upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, June 13th. Seven investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, IDEXX Laboratories currently has an average rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.